Showing 21 - 30 of 551,423
Persistent link: https://www.econbiz.de/10003511733
Die demographische Entwicklung und der medizinisch-technische Fortschritt gelten als die beiden wichtigsten Gründe für den Anstieg der Gesundheitsausgaben. Der vorliegende Übersichtsartikel betrachtet den Einfluss der Alterung auf die Gesundheitsausgaben anhand der so genannten...
Persistent link: https://www.econbiz.de/10009500551
Persistent link: https://www.econbiz.de/10013360333
We use a calibrated stochastic life-cycle model of endogenous health spending, asset accumulation and retirement to investigate the causes behind the increase in health spending and life expectancy over the period 1965-2005. We estimate that technological change along with the increase in the...
Persistent link: https://www.econbiz.de/10003925549
Innovation is part idea generation and part development. We build a model of "innovating-by-doing," whereby ideas come to practitioners. Successful innovation requires that practitioners' ideas be developed through costly effort. Our model nests existing theories of laboratory research and...
Persistent link: https://www.econbiz.de/10012500504
Persistent link: https://www.econbiz.de/10003511797
There is agreement among health economists that on the whole medical innovation causes health care expenditures (HCE) to rise. This paper analyzes for which diagnoses and in which age groups HCE per patient have grown significantly faster than average HCE. We distinguish decedents (patients in...
Persistent link: https://www.econbiz.de/10012437174
There is agreement among health economists that on the whole medical innovation causes health care expenditures (HCE) to rise. This paper analyzes for which diagnoses and in which age groups HCE per patient have grown significantly faster than average HCE. We distinguish decedents (patients in...
Persistent link: https://www.econbiz.de/10012423504
This paper discusses the relationship between medical innovations and ageing from a health economics perspective and surveys empirical evidence on medical R&D incentives, R&D costs of pharmaceuticals, and the cost-effectiveness of health innovations. Particular focus is on the endogeneity of...
Persistent link: https://www.econbiz.de/10012653346